Literature DB >> 19615948

Association between antiepileptic drug switching and epilepsy-related events.

Ryan N Hansen1, Jonathan D Campbell, Sean D Sullivan.   

Abstract

Switching between bioequivalent antiepileptic drugs (AEDs) in patients with epilepsy remains a concern because of possible untoward effects owing to a narrow therapeutic range. We investigated the association between switching A-rated AEDs and epilepsy-related events. We conducted a case-control study using claims from the MarketScan database. Cases were defined by an emergently treated epilepsy-related event with the primary diagnosis of epilepsy. Controls had an epilepsy outpatient office visit. Eighty-four of 757 (11.1%) cases and 147 of 2271 (6.5%) controls experienced an A-rated switch. The odds of an epilepsy-related event were 1.78-fold higher for switchers (95% CI 1.35 to 2.36) and, when adjusted for gender and total number of AED prescriptions filled, 1.57-fold higher (95% CI=1.17-2.10). Switching between A-rated formulations of AEDs is associated with an increased risk of emergently treated epilepsy-related events. These findings suggest that care should be taken when considering a switch between A-rated AEDs in patients with epilepsy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615948     DOI: 10.1016/j.yebeh.2009.05.019

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  12 in total

1.  Switching of antiepileptic drug formulations.

Authors:  J Nile Barnes; Karen L Rascati
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

2.  Exploring community pharmacists' views on generic medicines: a nationwide study from Malaysia.

Authors:  Chee Ping Chong; Mohamed Azmi Hassali; Mohd Baidi Bahari; Asrul Akmal Shafie
Journal:  Int J Clin Pharm       Date:  2011-01-13

3.  Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Authors:  Daniel M Hartung; Luke Middleton; Leanne Svoboda; Jessina C McGregor
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

4.  Topiramate use does not reduce flares of inflammatory bowel disease.

Authors:  Seth D Crockett; Robin Schectman; Til Stürmer; Michael D Kappelman
Journal:  Dig Dis Sci       Date:  2014-02-07       Impact factor: 3.199

5.  Refilling and switching of antiepileptic drugs and seizure-related events.

Authors:  J J Gagne; J Avorn; W H Shrank; S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2010-07-14       Impact factor: 6.875

6.  Factors associated with seizure recurrence in epilepsy patients treated with antiepileptic monotherapy: A retrospective observational cohort study using US administrative insurance claims.

Authors:  Natalia Shcherbakova; Karen Rascati; Carolyn Brown; Kenneth Lawson; Suzanne Novak; Kristin M Richards; Linda Yoder
Journal:  CNS Drugs       Date:  2014-11       Impact factor: 5.749

Review 7.  Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Margaret R Stedman; Ellen J Bubrick; Joshua J Gagne; Alexander S Misono; Joy L Lee; M Alan Brookhart; Jerry Avorn; William H Shrank
Journal:  Drugs       Date:  2010-03-26       Impact factor: 9.546

8.  Patterns of seizure prophylaxis after oncologic neurosurgery.

Authors:  Brett E Youngerman; Evan F Joiner; Xianling Wang; Jingyan Yang; Mary R Welch; Guy M McKhann; Jason D Wright; Dawn L Hershman; Alfred I Neugut; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2019-12-13       Impact factor: 4.130

9.  Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.

Authors:  Maria Stella Vari; Francesca Pinto; Elisabetta Mencaroni; Giovanna Giudizioso; Carlo Minetti; Angela La Neve; Tiziana Francavilla; Marta Piccioli; Salvatore Striano; Luigi del Gaudio; Pierangelo Tovo; Pasquale Striano; Alberto Verrotti
Journal:  Clin Drug Investig       Date:  2016-01       Impact factor: 2.859

10.  Attention-deficit/hyperactivity disorder medication and seizures.

Authors:  Kelsey K Wiggs; Zheng Chang; Patrick D Quinn; Kwan Hur; Robert Gibbons; David Dunn; Isabell Brikell; Henrik Larsson; Brian M D'Onofrio
Journal:  Neurology       Date:  2018-02-23       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.